These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Non-cardiogenic pulmonary edema complicating intermediate and high-dose Ara C treatment for relapsed acute leukemia. Jehn U; Göldel N; Rienmüller R; Wilmanns W Med Oncol Tumor Pharmacother; 1988; 5(1):41-7. PubMed ID: 3367672 [TBL] [Abstract][Full Text] [Related]
6. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536 [TBL] [Abstract][Full Text] [Related]
7. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol. Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387 [TBL] [Abstract][Full Text] [Related]
8. A pilot study of continuous infusion Ara-C in combination with rhG-CSF in relapsed childhood acute myeloid leukemia. Laver J; Shearer P; Krance R; Hurwitz CA; Srivastava DK; Weinstein HJ; Mirro J Leuk Lymphoma; 1997 Aug; 26(5-6):589-93. PubMed ID: 9389365 [TBL] [Abstract][Full Text] [Related]
9. High-dose cytarabine and recombinant human granulocyte colony-stimulating factor for the treatment of resistant acute myelogenous leukemia. Schiller G; Emmanoulides C; Iastrebner MC; Lee M; Naeim F Leuk Lymphoma; 1996 Feb; 20(5-6):427-34. PubMed ID: 8833398 [TBL] [Abstract][Full Text] [Related]
10. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890 [TBL] [Abstract][Full Text] [Related]
11. Pulmonary complications of cytosine-arabinoside therapy: radiographic findings. Tham RT; Peters WG; de Bruïne FT; Willemze R AJR Am J Roentgenol; 1987 Jul; 149(1):23-7. PubMed ID: 3495987 [TBL] [Abstract][Full Text] [Related]
12. Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study. Ochs J; Rivera GK; Pollock BH; Buchanan G; Crist W; Freeman AI Cancer; 1990 Oct; 66(8):1671-7. PubMed ID: 2208021 [TBL] [Abstract][Full Text] [Related]
14. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study. Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091 [TBL] [Abstract][Full Text] [Related]
15. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Wrzesień-Kuś A; Robak T; Wierzbowska A; Lech-Marańda E; Pluta A; Wawrzyniak E; Krawczyńska A; Kuliczkowski K; Mazur G; Kiebiński M; Dmoszyńska A; Wach M; Hellmann A; Baran W; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Ann Hematol; 2005 Sep; 84(9):557-64. PubMed ID: 15856358 [TBL] [Abstract][Full Text] [Related]
16. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation. Gordon BG; Warkentin PI; Strandjord SE; Abromowitch M; Bayever E; Harper JL; Coccia PF Bone Marrow Transplant; 1997 Jul; 20(1):5-10. PubMed ID: 9232249 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951 [TBL] [Abstract][Full Text] [Related]
18. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia. Lockhart S; Plunkett W; Jeha S; Ramirez I; Zipf T; Cork A; Pinkel D J Clin Oncol; 1994 Mar; 12(3):587-95. PubMed ID: 8120558 [TBL] [Abstract][Full Text] [Related]
19. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Ravindranath Y; Chang M; Steuber CP; Becton D; Dahl G; Civin C; Camitta B; Carroll A; Raimondi SC; Weinstein HJ; Leukemia; 2005 Dec; 19(12):2101-16. PubMed ID: 16136167 [TBL] [Abstract][Full Text] [Related]
20. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients. Li JM; Shen Y; Wu DP; Liang H; Jin J; Chen FY; Song YP; Song EY; Qiu XF; Hou M; Qiu ZC; Shen ZX Int J Hematol; 2005 Jul; 82(1):48-54. PubMed ID: 16105759 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]